Dr. Stephen Quake, President of the Chan Zuckerberg Biohub Network, spoke to CANCER BUZZ about the application of liquid biopsies across multiple cancer stages and their potential to improve patient outcomes, minimize financial toxicity, and create health equity through greater testing access and lower cost. He identified trends that are shaping the future of cancer research, including the amazing developments in new cancer screens for diseases where they don't currently exist. Hear about the hydroxymethylation measurement techniques pioneered by his lab, which is the exact science now being used by many investigational multi-cancer early detection (MCED) assays to screen for cancers which don't have guideline-approved tests, like pancreatic and ovarian cancer.

Guest:

Stephen Quake, PhD

Professor of Bioengineering and Applied Physics, Stanford University

Co-President, Chan Zuckerberg Biohub Network

Resources:

• Stanford Quake Lab
• Chan Zuckerberg Biohub Network
• New Chan Zuckerberg Biohub awards foster research collaborations
• Transforming Complex to Clear: Precision Medicine Resources
• [Blog] Barriers to Liquid Biopsy
• [Podcast] What You Need to Know about Liquid Biopsy
• Improving the Timeliness of Biomarker Testing by Using Liquid Biopsy When Tissue Samples are Insufficient for Testing
• [Podcast] Financial Barriers to Biomarker Testing
• Biomarker Testing: Cost and Coverage
• Bluestar Genomics | Liquid Biopsy Cancer Detection